|
|
Diagnostic Value of TIMD4 in the Prognosis of Patients with CNSCLC |
WANG Ru, ZHANG Min, LI Jun-she |
The First Department of Hengshan District People's Hospital,Yulin Shaanxi 719199 |
|
|
Abstract 【Objective】To investigate the diagnostic value of T cell immunoglobulin and mucin domain 4 (TIMD4) in the prognosis of patients with central non-small cell lung cancer (CNSCLC).【Methods】A total of 139 patients with CNSCLC who received treatment in our hospital from April 2015 to June 2017 were selected as the research subjects. All patients were treated with transcatheter arterial chemoembolization (TACE) combined with percutaneous radiofrequency ablation (RFA). According to the 3-year prognosis,patients were divided into the survival group and the death group. Mononuclear cells were isolated by Ficoll density gradient centrifugation method. Western blotting was used to detect the expression level of TIMD4 in mononuclear cells,and the diagnostic value of TIMD4 in the prognosis of CNSCLC patients was analyzed. 【Results】The expression level of TIMD4 in the survival group and the death group showed a decreasing trend over time (P<0.05). The expression levels of TIMD4 at T1 and T2 in the survival group were lower than those in the death group,and the differences were statistically significant (P<0.05). The median survival time of the high TIMD4 group was lower than that of the low TIMD4 group; And the difference was statistically significant (P<0.05). COX regression analysis showed that TNM staging and T2-TIMD4 were independent risk factors for the prognosis of CNSCLC patients (P<0.05),while the differentiation degree and taking targeted drugs were independent protective factors for the prognosis of CNSCLC patients (P<0.05). The fitting curve of the nomogram regression model constructed by TNM staging,degree of differentiation,taking targeted drugs and T2-TIMD4 had a higher degree of coincidence with the ideal curve,whose consistency index C-index was 0.803. 【Conclusion】High TIMD4 expression in CNSCLC patients indicates a high risk of poor prognosis. The nomogram regression model based on TIMD4 has high accuracy and discrimination,which can evaluate the prognosis of CNSCLC patients.
|
Received: 08 March 2022
|
|
|
|
|
[1] 倪千喜,蔡奕龙,王亮,等. 中央型非小细胞肺癌肿瘤体积与位置对调强放射治疗靶区剂量的影响[J].肿瘤学杂志,2019,25(7):634-636.
[2] 马军朋,卢伟,杨超,等. 经导管动脉化疗栓塞联合经皮射频消融治疗中央型非小细胞肺癌[J].中国介入影像与治疗学,2018,15(9):517-520.
[3] MEYERS J H,CHAKRAVARTI S,SCHLESINGER D,et al.TIM-4 is the ligand for TIM-1,and the TIM-1-TIM-4 interaction regulates T cell proliferation[J].Nat Immunol,2005,6(5):455-464.
[4] MIZUI M,SHIKINA T,ARASE H,et al. Bimodal regulation of T cell-mediated immune responses by TIM-4[J].Int Immunol,2008,20(5):695-708.
[5] ZHANG Q,WANG H,WU X,et al. TIM-4 promotes the growth of non-small-cell lung cancer in a RGD motif-dependent manner[J].Br J Cancer,2015,113(10):1484-1492.
[6] LIU W,WANG H,BAI F,et al. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB[J].Cell Prolif,2020,53(3):e12776.
[7] TANG X,WANG J,XIA X,et al. Elevated expression of ciRS-7 in peripheral blood mononuclear cells from rheumatoid arthritis patients[J].Diagn Pathol,2019,14(1):11.
[8] 辛杰晶,徐娟,申洁,等. 非酒精性脂肪性肝病患者外周血单个核细胞中沉默信息调节因子7的水平及其意义[J].医学临床研究,2022,39(8):1228-1231.
[9] 刘新,沈世林,王玉萍,等. 中晚期非小细胞肺癌的综合介入治疗现状[J].中华肺部疾病杂志(电子版),2017,10(4):486-489.
[10] CONG Y,SUN B,WANG J,et al. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer[J].Thorac Cancer,2019,10(7):1567-1575.
[11] YANO H,MOTOSHIMA T,MA C,et al. The significance of TIMD4 expression in clear cell renal cell carcinoma[J].Med Mol Morphol,2017,50(4):220-226.
[12] 张铁梅,张军,周德俊,等. 非小细胞肺癌组织中脆性位点相关的肿瘤抑制因子的表达及其与患者预后的关系[J].中华肿瘤杂志,2019,41(11):826-830. |
|
|
|